Plasma 8-isoprostane is increased in preterm infants who develop bronchopulmonary dysplasia or periventricular...

Area of Science:

• Neonatology
• Oxidative Stress Research
• Biomarker Discovery

Background:

• Extremely low birth weight infants (ELBWIs) are susceptible to oxidative damage, increasing the risk of conditions like bronchopulmonary dysplasia (BPD).
• Identifying reliable biomarkers for oxidative stress and predicting BPD risk in ELBWIs is crucial for timely intervention.
• N-acetylcysteine (NAC) has been investigated for its potential antioxidant effects in this vulnerable population.

Purpose of the Study:

• To evaluate plasma free 8-epi-prostaglandin F(2alpha) (8-isoprostane) and ascorbyl radical as indicators of oxidative damage in ELBWIs.
• To assess the impact of N-acetylcysteine (NAC) administration on these oxidative stress markers.
• To determine if these markers can predict the development of BPD or other adverse outcomes in ELBWIs.

Main Methods:

• Plasma samples were collected on days 3 and 7 from ELBWIs participating in a randomized controlled trial of intravenous NAC versus placebo.
• Plasma 8-isoprostane was quantified using an enzyme immunoassay kit.
• Ascorbyl radical concentration was measured using electron spin resonance spectroscopy.

Main Results:

• 8-isoprostane concentrations were significantly higher on days 3 and 7 in infants who later developed BPD or died compared to survivors without BPD.
• Elevated 8-isoprostane levels on day 3 were associated with an increased risk of developing periventricular leukomalacia.
• NAC treatment did not significantly alter 8-isoprostane or ascorbyl radical levels, and ascorbyl radical levels decreased over time in all infants.

Conclusions:

• Plasma 8-isoprostane shows promise as a predictive biomarker for BPD development in ELBWIs.
• Ascorbyl radical levels, while altered in infants with periventricular leukomalacia, did not appear to be a reliable predictor of BPD in this study.
• Further research is warranted to explore the therapeutic potential of NAC and the clinical utility of 8-isoprostane as a risk assessment tool in ELBWIs.